Skip to content
Search for:
Registration & Accommodation
Registration
Accommodation
Pullman Paris Montparnasse
Invitation Letter
Main Entrance
Welcome Note
Congress Co-Chairs
Program
Scientific Program
Timetable
Main Topics
Faculty
Abstract Submission
Congress Information
General Information
CME Accreditation
COMy 2024 Awards
About Paris
Support & Exhibition
Contact
Compliance
Italian Agency
Contact Us
Search for:
Springer Evaluation Form
Springer Evaluation Form
Adam Barkay
2021-04-28T15:01:26+00:00
Live symposium: Thursday, 6
th
May 2021
13:30-15:00 CEST | 07:30-09:00 EDT (90 mins)
CME accredited
NACCME designates this live digital symposium for a maximum of 1.5
AMA PRA Category 1 credits™
.
If you would like to receive a certificate for your attendance at the live event, please add the below information and complete the evaluation survey. You will then be sent your certificate shortly:
Full Name
*
First
Last
Email
*
Profession
*
Degree
*
Evaluation form
Question 1
i). How would you rate the overall quality of the symposium?
*
1= Poor, 5= Excellent
1
2
3
4
5
ii) What did you like best about the symposium or was most beneficial to you?
iii) Was there any aspect of the program that you feel should be improved or was least beneficial to you?
Question 2
How well did the symposium fulfil the following learning objectives?
1=Very little, 5=Strongly
After participating in the symposium I am now able to…
Identify and explain toxicity issues related to new treatments for multiple myeloma
*
Identify and explain toxicity issues related to new treatments for multiple myeloma
1
2
3
4
5
Debate how to appropriately manage multiple myeloma-related cardiovascular toxicities
*
Debate how to appropriately manage multiple myeloma-related cardiovascular toxicities
1
2
3
4
5
Discuss and analyze the advances in the management of cytokine-release syndrome, neurotoxicities, and ocular toxicities, caused by novel treatments like CAR-T cell therapy and antibody–drug conjugates
*
Discuss and analyze the advances in the management of cytokine-release syndrome, neurotoxicities, and ocular toxicities, caused by novel treatments like CAR-T cell therapy and antibody–drug conjugates
1
2
3
4
5
Question 3
How useful was each session? Please rate the individual sessions based on knowledge, expertise, and teaching ability
1=Not Useful, 5=Very Useful
Managing multiple myeloma-related cardiotoxicities – Saad Usmani, USA
*
Managing multiple myeloma-related cardiotoxicities –
Saad Usmani, USA
1
2
3
4
5
Managing cytokine release syndrome after CAR-T cell therapy – Noopur Raje, USA
*
Managing cytokine release syndrome after CAR-T cell therapy –
Noopur Raje, USA
1
2
3
4
5
Managing neurotoxicities after CAR-T cells and T cell engagers – Luciano Costa, USA
*
Managing neurotoxicities after CAR-T cells and T cell engagers –
Luciano Costa, USA
1
2
3
4
5
Managing ocular adverse events after antibody drug-conjugates – Marc Labetoulle, France
*
Managing ocular adverse events after antibody drug-conjugates –
Marc Labetoulle, France
1
2
3
4
5
Faculty discussion and audience questions
*
Faculty discussion and audience questions
1
2
3
4
5
Question 4
As a result of viewing this symposium, will you make any measurable changes in your daily practice?
*
Yes
Possibly, after additional training/information
No, but the content affirms my current practice
No, I am unable to implement this information
If YES, can you provide an example of how this event will influence your future practice?
If NO, what are the barriers that prevent you from making changes?
Question 5
Are there any topics that you would like to see covered in future educational activities within this therapeutic area?
Yes
No
If YES, please specify the topics you would like to learn more about?
Question 6
Do you agree that the presented information was overall free of commercial and other bias?
*
I agree there was no commercial or other bias
Disagree, I thought there was commercial bias
Disagree, I thought there was another bias
Please state
Question 7
Would you recommend this symposium to your colleagues?
Yes
No
Δ
Page load link
Go to Top